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a b s t r a c t
Integrase-defective lentiviral vectors (ID-LVs) show several hallmarks of conventional lentiviral vectors
such as absence of cytotoxic effects and long-term expression in non-replicating target cells. The inte-
gration rate of ID-LVs into the genome of target cells is dramatically reduced, which enhances safety and
opens perspectives for their use in vaccine development. ID-LVs have been shown to be effective vac-
cines in mouse models, but functional studies with human cells in vitro and in vivo are lacking. Here, we
evaluated whether ID-LVs expressing combinations of cytokines (GM-CSF/IL-4 or GM-CSF/IFN-) used
to transduce human monocytes would result in functional “induced dendritic cells” (iDCs). Overnight
transduction of monocytes with high titer ID-LVs generated highly viable (14 days) and immunopheno-
typically stable iDCsexpressingGM-CSF/IL-4 (“SmartDCs”)orGM-CSF/IFN- (“SmyleDCs”). SmartDCsand
SmyleDCs maintained in vitro continuously secreted the transgenic cytokines and showed up-regulation
of several endogenously produced inﬂammatory cytokines (IFN-, IL-2, -5, -6, and -8). Both iDC types
potently stimulated T cells in mixed lymphocyte reactions at levels comparable to conventional DCs
(maintained with exogenous cytokines). A single in vitro stimulation of CD8+ T cells with autologous
SmartDCs or SmyleDCs pulsed with peptide pools of pp65 (a human cytomegalovirus antigen) resulted
in high expansion of central memory and effector memory CTLs reactive against different pp65 epi-
topes. We further evaluated the effects of SmartDCs and SmyleDCs to expand anti-pp65 CTLs in vivo
(−/−) (−/−)using immune deﬁcient NOD/Rag1 /IL-2r (NRG) mice. NRG mice immunized subcutaneously
with SmartDCs or SmyleDCs co-expressing the full-length pp65 were subsequently infused with autolo-
gous CD8+ T cells. Both types of iDCs effectively stimulated human CTLs reactive against different pp65
antigenic determinants in vivo. Due to the simplicity of generation, robust viability and combined capac-
ity to stimulate homeostatic, antigenic and multivalent responses, iDCs are promising vaccines to be
n of lyexplored in immunizatioAbbreviations: SmartDCs, self-differentiated myeloid-derived antigen-
resenting-cells reactive against tumors-DCs; SmyleDCs, self-differentiated
yeloid-derived lentivirus-induced-DCs; IC-LV, integrase-competent lentiviral
ector; ID-LV, integrase-defective lentiviral vector.
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1. Introduction
Despite current therapeutic developments, high frequencies
of patients who undergo hematopoietic stem cell transplantation
(HSCT) experience episodes of human cytomegalovirus (HCMV)
viral reactivationorbecomenewly infected,whicharemajor causes
of morbidity and death for the affected patients. Tetramer mon-
itoring studies post-HSCT have demonstrated that the presence
and expansion of HCMV-reactive cytotoxic T lymphocytes (CTL)
post-reactivation seemed to protect the patients against recur-
rent reactivations [1]. No clinical vaccines are currently available
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uch as live attenuated, DNA subunit and recombinant vaccines
re in development [2]. Studies correlating the level of innate
nd adaptive immune responses with the disease outcome have
emonstrated that the strongest protection against HCMV is medi-
ted by virus-speciﬁc T-cell memory responses and recovery of
atural killer cell function [3].
Dendritic cells (DCs) are potent immune adjuvants capable of
riming adaptive long-lasting immune responses and of reverting
hronicity-induced immunologic anergy or tolerance. Therefore,
heir use toprevent acute infectionsor to resolve chronicpathogens
n lymphopenic hosts has broad potential. Phase I/II studies includ-
ng allogeneic SCT recipients at high risk for HCMV disease who
ere vaccinated with peptide-loaded DCs showed a signiﬁcant
linical beneﬁt with clear induction of HCMV-speciﬁc cytotoxic
lymphocytes (CTLs) [4]. Unfortunately, current ex vivo DC pro-
uction methodologies in the laboratory remain highly costly and
nconsistent, demand several days for production and are imprac-
ical for large-scale and routine clinical use.
In order to overcome these limitations, our novel approach is
he use of lentiviral vectors (LVs) expressing cytokine combina-
ions capable to induce monocytes to autonomously differentiate
nto dendritic cells after only one day of ex vivo gene transfer. The
nal cell product is called “induced DCs” (or iDCs). We have pre-
iously demonstrated in human and mouse systems that ex vivo
ransduction of DC precursors with LVs for production of granulo-
ytemacrophage colony stimulating factor (GM-CSF), interleukin-4
IL-4) and tumor antigens induced self-differentiation of potent
nti-cancer therapeutic DC vaccines (“self-differentiated myeloid
erived antigen presenting cell reactive against tumors – Smart-
Cs”) [5,6]. Recently,wehavedevelopeda28-hmethod compatible
ith good manufacturing practices (GMP) for production of cry-
preserved SmartDCs in sufﬁcient amounts for clinical cancer
mmunotherapy studies [7].
Another explored use of iDCs is to accelerate the immune
egeneration of patients receiving CD34+ hematopoietic SCT by
meliorating the homeostatic reconstitution and enhancing anti-
en presentation in lymphopenic recipients. After HSCT, patients
how slow DC recovery, requiring approximately 60 days in order
o reach pre-transplant levels [8]. We have recently established
proof-of-concept animal model using NOD/Rag1(−/−)/IL-2r(−/−)
NRG) immune deﬁcient mice which lack T, B and NK cells and can
e repopulated with cells from the human peripheral blood [9]. We
howed that human SmartDCs expressing the HCMV pp65 (65kDa
ower matrix phosphoprotein) antigen dramatically enhanced the
ngraftment, in vivo expansion and functionality of autologous
uman T cells reactive against pp65 in NRG mice [10]. Quantita-
ive pp65 CTL responses produced in the mice could be directly
easured by tetramer assay and ELISPOT. We observed a signif-
cantly faster expansion of human CD4+ and CD8+ T cells in the
pleen and peripheral blood and a massive recruitment of lym-
hocytes to the SmartDC/pp65 injection site [10]. Thus, this model
onﬁrmed our hypothesis that preconditioning the host with iDCs
roducing homeostatic (mediated through expression of human
ytokines) and antigen-speciﬁc (mediated through expression of
p65) stimuli accelerated human T cell responses in a lymphopenic
ost.
A major limitation in the use of LVs for vaccine develop-
ent is their intrinsic potential to integrate in the genome of the
nfected cells which, at least theoretically, could cause insertional
utagenesis or “genotoxicity” [11,12]. Lentiviral gene transfer
nto hematopoietic stem cells with lentiviral vectors has recently
eached the clinics for gene therapy replacement and was shown
o be safe [13]. On the other hand, the use of LVs for immunization
pproaches is alsoanexpandingﬁeld [6], but so faronlypre-clinical,
ince following a risk/beneﬁt calculation, integrating viruses are
sually perceived as non-safe for vaccine development.ine 30 (2012) 5118–5131 5119
It is known that non-integrated lentiviral DNA can support tran-
scription, and, for growth-arrested cells, “episomal” LV canproduce
steady high-level transgene expression [14–17]. Recently, LVs con-
taining a mutated integrase (heretofore named integrase defective
LVs or ID-LVs) have been tested in several animal immunization
studies, demonstrating their efﬁcacy [18,19]. Although one report
demonstrated that human DCs can be transduced with ID-LVs [20],
there was so far no information regarding their functionality in the
stimulation of human T cell responses in vivo.
Thus, here we further validated iDCs in order to address trans-
lationally relevant aspects regarding bio-safety and function. iDCs
engineered with ID-LV expressing GM-CSF/IL-4 were character-
ized in vitro and in vivo. In addition, in order to evaluate a novel
modality of ID-LV expressing a cytokine relevant for stimulation
and/or expansion of NK cells and central memory T cells, we tested
if human interferon alpha (IFN-) co-expressed with GM-CSF in
monocytes would also result into iDCs. The combination of GM-
CSF/IFN- for the production of clinical DCs is currently being
explored [21], but their co-expression in DCs via gene transfer has
not been reported. This goal was achieved, and this new modality
of iDC showed to be highly viable and functional in vitro and in vivo.
2. Materials and methods
2.1. Vector construction
The construction of the vectors LV-GM-CSF-P2A-IL-4 (LV-
G24), RRL-cPPT-CMV-pp65 (65kDa phosphoprotein) and
RRL-cPPT-CMV-fLUC (ﬁreﬂy luciferase) were previously described
[10]. For the generation of the vector RRL-cPPT-CMV-GM-
CSF-P2A-IFN- (LV-G2) overlapping-PCR was performed
using cDNAs of human GM-CSF and human IFN- (Origene
technologies, Inc. Rockville, USA) as templates interspaced
with a 2A element of porcine teschovirus (P2A). The strat-
egy of LV construction with P2A element was previously
described [22]. Primers used to generate the interspacing P2A





products were digested with restriction enzymes XbaI and XmaI
and inserted into the multiple cloning site of RRL-cPPT-CMV-MCS
vector. The structural integrity of all constructs was conﬁrmed by
restriction digestion and sequencing analysis.
2.2. Integrase-defective lentivirus (ID-LVs) production
Large scale lentivirus production was performed by transient
co-transfection of human embryonic kidney 293T cells as for-
merly described [23]. 293T cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and penicillin (100U/ml) and streptomycin
(100mg/ml). The combination of the following packaging plas-
mids was used in the co-transfection: the plasmid containing the
lentiviral vector expressing the cytokines, the plasmid expressing
rev (pRSV-REV), the plasmid expressing gag/pol containing a D64V
point mutation in the integrase gene (pcDNA3g/pD64V.4xCTE),
and the plasmid encoding the VSV-G envelope (pMD.G). The virus
supernatants were concentrated by ultracentrifugation and the
titers were evaluated by assessing p24 antigen concentration with
enzyme-linked immunoabsorbent assay (ELISA) (Cell Biolabs, Inc.,
San Diego, USA). One g of p24 equiv./ml corresponds to approxi-
mately 1×107 infective viral particles/ml.
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.3. Generation of human SmyleDCs and SmartDCs with ID-LVs
Peripheral blood mononuclear cells (PBMCs) were obtained
rom HLA-A*0201/HLA-B*0702 positive HCMV seropositive adult
ealthy volunteers and all studies were performed in accordance
ith protocols approved by the Hannover Medical School Ethics
eview Board. HCMV seropositivity was assessed by the pres-
nce of HCMV-reactive immunoglobulin (Ig) G and/or IgM. CD14+
onocyteswere isolated fromPBMCs obtained from leukapheresis
sing CD14 isolation beads (Miltenyi Biotech, Bergisch-Gladbach,
ermany). For production of conventional IL-4-DCs, monocytes
ere kept in culturewith serum-freeCellgromedium (Lonza, Basel,
witzerland) in the presence of recombinant human GM-CSF and
L-4 (50ng/ml each, Cellgenix, Freiburg, Germany), whereas con-
entional IFN--DCs were maintained in the presence of 50ng/ml
M-CSF and 1000U/ml IFN- (PBL InterferonSource, NJ, USA).
ytokines were replenished every 3 days. For lentiviral gene trans-
er, the monocytes were kept in culture with serum-free Cellgro
edium in the presence of recombinant human GM-CSF and IL-
(50ng/ml each) for 8h prior to transduction. For generation
f SmyleDCs, 2.5g/mL p24 equivalent of ID-LV-G2 was used,
hereas 2.5g/mL p24 equivalent of ID-LV-G24 was used for gen-
ration of SmartDCs. 5×106 CD14+ monocytes were transduced
t the multiplicity of infection (M.O.I.) of 5 in the presence of
g/ml protamine sulfate (Valeant, Dusseldorf, Germany) for 16h.
fter transduction, the cells were washed twice with phosphate-
uffered saline (PBS) and further maintained in culture with
erum-free Cellgro medium. iDCs were harvested after 7 or 14 days
f culture. For in vivo experiments, transduced monocytes were
esuspended in PBS, washed and directly used for mice injection.
he number of viable counts was determined with trypan blue
xclusion.
.4. Analyses of cytokines and transgene expression
ELISA (Mabtech, Minneapolis, USA) was used to quantify the
ccumulated level of human cytokines GM-CSF, IFN- and IL-4
ecreted in the supernatant of iDC cultures. For detection of mul-
iple cytokines secreted in iDC supernatants, in mixed lymphocyte
eactions or in vitro T cell stimulation assays, we used multiplex
uminex bead kit according to the manufacturer’s protocol (Mil-
iplex Milipore, Billerica, USA). GM-CSF, IFN- and IL-4 protein
xpression in transduced 293T cell lysates and supernatants was
etermined by Western blot analyses (Bio-Rad, Munich, Germany).
etection of intracellular HCMV pp65 expression in SmyleDCs
nd SmartDCs was performed by intracellular staining and ﬂow
ytometry. iDCs were maintained in culture for 7, 14 and 21
ays and immune-labeled for DC surface antigens. After wash-
ng off unbound antibodies, cells were subsequently permeabilized
ith BD cytoﬁx/cytoperm solution (Becton Dickinson GmbH, Hei-
elberg, Germany) and incubated with ﬂuorescein isothiocyanate
FITC)-conjugated mouse monoclonal antibody against CMV-pp65
Pierce Biotechnology, Rockford, USA) in a 1:20 dilution with BD
erm/wash solution as indicated by the manufacturer’s instruc-
ion. After 30min incubation in the dark, cells were washed and
nalyzed by ﬂow cytometry.
.5. Allogeneic mixed lymphocyte reactions
Antigen presenting cells (SmyleDCs, SmartDCs or PBMCs) were
rradiated with 30Gy, and CD3+ T cells isolated with immunobeads
Miltenyi Biotech) were used as responders. Different APC or PBMC
atios were co-cultured with 1×105 allogeneic CD3+ T cells (2,
and 20) in rounded-bottom 96-well plates in a total volume of
00L Cellgro medium. Triplicate wells were set up for each reac-
ion and ratio. The reactions were incubated for 6 days at 37 ◦C. Forine 30 (2012) 5118–5131
the last 18h of the culture, the supernatants from each reaction
were collected for multiplex luminex bead kit. 1Ci/well of [3H]
Thymidinewasaddedand [3H]Thymidine incorporation in thecells
was measured on a -scintillation counter. The stimulatory capac-
itywas determinedwith stimulation index (SI) = counts perminute
(cpm) of stimulated T cells and stimulators/cpm of unstimulated T
cells.
2.6. Intracellular staining of stimulated NK cells
To determine the production of cytokines byNK cells stimulated
with iDCs, autologous NK cells were freshly isolated from PBMCs
and co-incubated with 7 day SmyleDCs or SmartDCs at 1–5 ratio
for 15–17h. Staining of surface antigens on stimulated CD3−CD56+
NK cells was performed at 4 ◦C for 30min. For analysis of IFN-
and TNF- intracellular staining, cells were washed and ﬁxed with
4% paraformaldehyde for 10min. After ﬁxation, cells were perme-
abilized with saponin buffer (PBS supplemented with 0.1% saponin
and 10mM HEPES) and stained with IFN- and TNF- mAb. After
30min incubation, cells were washed three times and the percent-
age of IFN- and TNF- positive NK cells was determined by ﬂow
cytometry.
2.7. Flow cytometry analyses of cell surface antigens
SmyleDCs and SmartDCs kept in culture for 7 and 14 days were
analyzed for their DC immunophenotype. Cell were harvested and
washed once with PBS and blocked with mouse IgG (50g/mL)
on ice for 15min followed by staining with a combination of
monoclonal antibodies; FITC-conjugated anti-human CD209, APC-
conjugated anti-human CD86, PE-conjugated anti-human CD80,
PerCP-conjugated anti-humanHLA-DR, PE-conjugated anti-human
CD14andPerCP-conjugated anti-humanCD123 (BectonDickinson)
for 30min in the dark. After washing off the unbound antibodies,
cells were then resuspended in 1% paraformaldehyde for ﬁxation
and further analyzed with a FACS Calibur apparatus (Becton Dick-
inson), using CellQuest software. Total viable cells were gated and
20,000 cells in gate were acquired.
2.8. Stimulation of pp65-reactive T cells in vitro
7-day conventional IL-4-DCs or IFN--DCs or iDCs (non-
matured) or 5-day iDCs further incubated for 2 dayswith 200 IU/ml
rhTNF-, 5 ng/ml rhIL-1B, 10ng/ml rhIL-6 and 1mg/ml PGE2
(matured) were harvested and loaded with 10g/ml PepTivator
CMV-pp65 overlapping peptide pool (Miltenyi Biotec). After 2h,
excess unloaded peptides were washed off. For assessing SmyleDC
and SmartDC expressing pp65, monocytes were co-transduced
with either ID-LV-G2 or ID-LV-G24 and ID-LV-pp65. For in vitro
stimulation assay, autologous CD8+ T cells were isolated from
PBMCs of CMV-seropositive donors with magnetic beads follow-
ing the manufacturer’s protocol (Miltenyi Biotec). SmyleDCs or
SmartDCs alone or peptide loaded DCs were co-cultured in a 24-
well-plate with 3×106 T cells/well at ratio of 1:100 (APC: T-cell) in
serum-free Cellgromedium. 1×106 autologous feeder cells (CD8−)
were gamma-irradiated with 30Gy and added to the culture. After
3 days, the cells were split and replenished on alternate days
with Cellgro medium containing IL-2 (10 IU/ml) (Novartis Pharma
GmbH, Germany) and kept at 37 ◦C. After 7 days of initiation of
culture, stimulated T cells were harvested and washed twice with
PBS and analyzed for their pp65-reactivity with tetramer staining.
PE-conjugated tetramers (HLA-A*0201-NLVPMVATV, pp65 amino
acids (aa) 495–503;HLA-B*0702-TPRVTGGGAM, pp65 aa 417–426;
Beckman coulter), ECD-conjugated anti-human CD3 and PCy7-
conjugated anti-human CD8 were used. In addition, the expanded
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sing FITC-conjugated anti-CD45RA, PCy5-conjugated anti-CD62L
Beckman Coulter). The cells were acquired and analyzed by ﬂow
ytometry using a FC500 apparatus (Beckman Coulter). In addi-
ion, T cells stimulated with iDCs co-expressing full-length pp65
transduced with ID-LV-pp65) were analyzed for IFN- production
y Enzyme Linked Immuno Spot Technique (ELISPOT). Stimulated
cells were seeded at a density of 20,000 cells per well in 96-
ell ELISPOT plate coated with anti-human IFN- (Mabtech AB,
ermany). The cells were incubated overnight in the presence
f 10g/ml of pp65 overlapping peptide pool. After incuba-
ion, cells were washed and plates were further incubated with
iotin-conjugated anti-human IFN- antibody followed by alkaline
hosphatase-conjugated streptavidin. Plateswere developed using
BT/BCIP liquid substrate (Sigma) and analyzed with an ELISPOT
eader (AELVIS GmbH, Germany).
.9. In vivo experiments with immunodeﬁcient NRG mice
Handling of mice for in vivo studies was previously described
10]. Brieﬂy, NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl (NOD/Rag1(−/−)/IL-
r(−/−), NRG)micewere bred andmaintainedunder pathogen free
ondition in an IVC system (BioZone, United Kingdom). All proce-
ures involving mice were reviewed and approved by the Lower
axony and followed the guidelines provided by the Animal Facility
t Hannover Medical School. For studies of human T cells engraft-
ent and antigen speciﬁc T cell expansion, mice were primed with
×105 SmyleDCs or SmartDCs (in 100L of PBS) co-transduced
ith ID-LV-pp65, by subcutaneous injection at the hind ﬂank using
27-gauge needle. The iDCs were allowed to self-differentiate in
ivo for 7 days. 5×106 cells freshly isolated autologous CD8+ T
ells (in 100L of PBS) were then intravenously infused through
he lateral tail vein. Peripheral blood and spleen were collected 14
ays after T cell injections. For determination of engraftment of
uman CD3+ CD8+ T cells in NRG mice and their anti-pp65 reactiv-
ty, peripheral blood samples were treated with erythrocyte lysis
uffer (0.83% ammonium chloride/20mMHepes, pH 7.2) for 1min,
ashed with PBS and stained with ﬂuoro-conjugated tetramers
nd antibodies; PE-conjugated pp65-reactive tetramers HLA-
*0201 (NLVPMVATV) andHLA-B*0702 (TPRVTGGGAM) (Beckman
oulter), APC-conjugated anti-human CD3 and FITC-conjugated
nti-human CD8were incubatedwith cells for 15min at room tem-
erature followed by erythrocyte lysis buffer incubation (Becton
ickinson). The FACS acquisition was performed in a FACS Calibur
ow cytometer (BectonDickinson) and the analysiswas performed
sing CellQuest software. For functional T cell assay, spleen cells
ere harvested and stained with APC-conjugated anti-human CD3
or 30min in the dark. After washing off unbound antibodies,
uman CD3+ T cells were sorted from splenocytes with a FAC-
Aria IIu apparatus (Becton Dickinson) and further analyzed with
LISPOT assay. 10,000 CD3+ T cells were seeded on IFN- antibody-
oated 96 wells plate, restimulated overnight with a pool of pp65
eptides or CEF peptides and the plates were further developed as
escribed above.
.10. In vivo viability of iDCs
Viability of iDCs in vivo was determined at different time points
ith in vivo bio-luminescence imaging analyses. NRG mice were
ubcutaneously injected at hind ﬂank with 5×105 SmyleDCs or
martDCs,markedwithﬁreﬂy luciferase after co-transductionwith
V-fLUC. Mice were anesthetized and intraperitoneally injected
ith aqueous solution of D-Luciferin (150mg/kg) 5min before
maging. The imaging was performed on day 7, 14, 30 and 90
ays after iDC injection using a CCD camera (IVIS, Caliper Life Sci-
nces, Mainz, Germany). Quantiﬁed bioluminescence consisted ofine 30 (2012) 5118–5131 5121
averaged photon radiance on the surface of the animal and was
expressed as photons/sec/cm2/sr (sr = steradian).
2.11. Statistical analysis
Parametric (t test) statistical analysis was used for determining
statistical signiﬁcance. All tests were two-sided, and p<0.05 was
considered signiﬁcant. Data was analyzed with GraphPad Prism 5
software (San Diego, CA, USA).
3. Results
3.1. Production and testing of lentiviral vectors
We constructed bicistronic self-inactivating lentiviral vec-
tor backbones co-expressing human GM-CSF/IFN- (LV-G2) or
GM-CSF/IL-4 (LV-G24) containing 2A elements interspacing the
transgenes (Fig. S1a). Through a ribosomal skipping mechanism,
a peptidic bond is missing between the 2A glycine and 2B pro-
line sites, resulting in synthesis of two individual proteins [24,22].
Using routine production methods [25], both vectors could be
consistently packaged as integration-competent lentiviral vectors
(IC-LVs) in 293T cells at high titers (Fig. S1b). Packaging of ID-LVs
in 293T cells was performed with a construct expressing the HIV
gag/pol mutated at the integrase gene (D64V). ID-LVs were pro-
ducedathigh titers (approximately3–4gp24/ml,whichwouldbe
equivalent to 3–4×107 particles/ml), showing slightly lower titers
than IC-LVs (4–5g p24/ml, Fig. S1b). Molecular analysis of the
transgenes expressed in 293T cells stably transduced with IC-LVs
was done by Western blot analyses of cell lysates and cell super-
natants. Intracellular GM-CSF protein was detectable in LV-G2
and LV-G24 transduced cells as a smear ranging from 15–25kDa,
whereas the secreted form was detected at 25kDa (Fig. S1c). GM-
CSF is synthesized in human cells as a precursor of 144 amino acids
(15kDa) with two glycosylation sites. Different molecular weight
forms of GM-CSF thus result from varying degrees of glycosylation.
In addition, the additional 21 aminoacids originating from the 2A
element resulted in an increment of 23kDa. Similarly, IFN- (IFN-
2b) and IL-4, also known to be glycosylated in human cells, were
both detectable as cytoplasmic and secreted proteins, running at
higher molecular weights than the recombinant bacteria protein
(Fig. S1d and e).
3.2. iDCs generated with ID-LVs produce several endogenous
cytokines
In previous work, we had shown that transduction of human
monocytes with the bicistronic vector IC-LV-G24 readily induced
outgrowth of SmartDCs. SmartDCs co-expressing HCMV pp65 pro-
tein as amodel antigen potently stimulated autologous CD8+ T cells
in vitro and accelerated the expansion of antigen speciﬁc immune
responses in vivo [10]. In this current study, we evaluated whether
ID-LVs could transduce monocytes and, upon DC differentiation,
the transgene expression would persist in order to maintain the
phenotype of the transduced cells. ID-LV expressing GFP used to
transduce monocytes resulted into approximately 10% transduc-
tion efﬁciency and, upon culture with recombinant GM-CSF and
IL-4, the differentiated DCs continued to express GFP for 2 weeks
(Fig. S2). Thus, our resultsusingmonocytesbasically conﬁrmedpre-
vious ﬁndings observed for transduced DCs transduced with ID-LV
[20].
Here, we also compared the effects of different cytokine
combinations (GM-CSF/IL-4 versus GM-CSF/IFN-) provided as
transgenes in LVs in the induction of DCs. Monocyte-derived DCs
maintained in the presence of recombinant cytokines (heretofore
Conv-IFN--DC or Conv-IL-4-DC) or transduced with the two types
5122 A. Daenthanasanmak et al. / Vaccine 30 (2012) 5118–5131
Fig. 1. Generation of SmyleDCs and SmartDCs with ID-LVs. (a) Morphology of SmyleDCs and SmartDCs (120×) after lentiviral induction and culture for 7 days under phase
contrast light microscopy. (b) Number of viable cells: SmyleDCs (grey) and SmartDCs (black) recovered from cultures on days 7 and 14 showed persistent viability (the
starting number of cells was 5×106 monocytes transduced with lentivirus at M.O.I. of 5). (c) Secreted transgenic cytokines: supernatants collected from iDC cultures on






























oultiplex luminex bead in supernatant collected from SmyleDC or SmartDC cultur
amples from different donors, n=3, *p<0.05.
f IC-LVs (LV-G24 or LV-G2) resulted in the differentiation of cells
ith similar DC immunophenotypes (Fig. S3). Thus, we proceeded
oward evaluation of safety-enhanced ID-LVs in their capacity to
nduce DCs as well. ID-LV-induced DCs were produced essentially
s previously described [10,26]. Shortly, CD14+ monocytes were
solated from cryopreserved PBMC from 3 different healthy donors
nd pre-conditioned with recombinant GM-CSF and IL-4 cytokines
or 8h prior to lentiviral addition, a critical step for efﬁcient
onocyte transduction. Bicistronic ID-LVs were used to transduce
onocytes at an estimated M.O.I. of 5. After transduction, the
ytokines and viruswerewashed-off from the culture, and the cells
ere maintained in the absence of exogenous cytokines in vitro.
tarting on day 3 after transduction, differentiation of monocytes
nto DCs was readily observed for both transduction groups. On
ay 7, cells transduced with the vector ID-LV-G2 showed typical
C morphology similar to SmartDCs generated with the ID-LV-
24 vector, but the cells were conspicuously smaller (Fig. 1a). We
amed these cells “self-differentiated myeloid-derived lentivirus-
nduced DCs”, or SmyleDCs. The number of immunophenotypically
table iDCs recovered 14 days after transduction was approxi-
ately 12% of the number of monocytes used for transduction,
hich probably reﬂects the LV transduction efﬁciency leading to
elective advantage of autonomously differentiated DCs (Fig. 1b).
easurement of the transgenic cytokines that accumulated in theell supernatant of SmyleDC and SmartDC cultures demonstrated
hat the levels of GM-CSF (1–2ng/ml) were constant and compara-
le between the two cultures (Fig. 1c). However, whereas the levels
f IFN- remained stable (4–6ng/ml) from days 7 to 14, IL-4 levelsday 7. Average and SD were calculated from independent experiments with three
substantiallydecreased (Fig. 1c). Themorepersistent co-expression
of both transgenes by SmyleDCs may explain the slightly higher
stability of SmyleDCs in vitro.
In addition to the cytokines expressed due to the lentiviral gene
delivery, we also evaluated if other cytokines were endogenously
produced by iDCs. Analyses of ten cytokines accumulated in the cell
culture medium were performed by bead array (Fig. 1d). Cytokines
detectable in SmyleDC and SmartDC cultures were IFN-, IL-2, IL-
5, IL-6, IL-8 (the later is a chemotactic factor and was produced at
signiﬁcantly higher levels by SmyleDCs than by SmartDCs). TNF-
, IL-1 and IL-10 were not detectable. The mixed pattern of the
cytokines indicated that several types of immune effectors (CTL,
Th1, Th2, NK, B cells, neutrophils, eosinophils) could be potentially
stimulated by iDCs.
3.3. SmyleDCs and SmartDCs generated with ID-LVs express DC
markers
Flow cytometry analyses of class II Major Histocompatibility
Complex (MHCII or HLA-DR for humans) and of co-stimulatory lig-
ands such as CD80 and CD86 provide important correlates of the
DC differentiation and functional status. Immunophenotypic anal-
yses of SmyleDCs and SmartDCs showed high frequencies (70%)
of cells expressing these immunorelevant DC markers at day 7 of
culture, which further increased for HLA-DR and CD86 on day 14
(CD80 expression decreased slightly) (Figs. 2a, b, S4a and b). As
expected, CD14, amonocytemarker,was down-regulated through-
out the culture. SmyleDCs showed signiﬁcantly lower expression












































































aig. 2. Immunophenotype of SmyleDCs and SmartDCs. Frequency of positive cells
myleDCs and SmartDCs analyzed by ﬂow cytometry on days 7 and 14: a and b, resp
btained from three different donors, n=3, *p<0.05.
f CD209 (also known as dendritic cell speciﬁc ICAM 3-Grabbing
on-integrin, DC-SIGN) than SmartDCs. As IL-4 is involved in
p-regulation of CD209 in conventional DCs generated with GM-
SF/IL-4, this recapitulates previous ﬁndings described for DCs
ultured in the presence of GM-CSF/IFN- [27]. CD123 (IL-3 recep-
or) which is a putative plasmacytoid DC (pDC) marker, was
xpressed at low levels (7%), indicating that, despite expression of
FN-, SmyleDCsmaintainedessentiallymyeloidDCcharacteristics
Figs. 2a, b, S4a and b).
.4. In vivo viability of iDCs
One of the main issues pertaining the clinical translation of
endritic cells maintained in vitro in the presence of recombinant
ytokines is their low viability after they are administered subcuta-
eously in patients. Possible reasons for the observed low viability
re the effects of the ex vivo culture itself, which may affect the
ngraftment of cells in vivo, and also the fact that once the cells
re taken off the culture they lack the cytokines that maintain their
iability ex vivo. We had previously demonstrated for mouse and
uman SmartDCs engineered with IC-LVs that these cells main-
ained high viability in vivo after injection under the skin for about
weeks and substantially lower after 2 months [5,10]. In order to
ollow the fate of the iDCsprogrammedwith ID-LVs in vivo, weused
he same experimental set up, i.e. we co-tranduced the iDCs with
IC-LV expressing the luciferase marking gene, injected the cells
ne day after transduction s.c. into NRG mice (n=3) and performed
equential optical imaging analyses. Conﬁrming our in vitro obser-
ations, the highest viability of iDCs in vivowasobservedduring the
nitial 2weeks after the injections. Analyses performedat later time
oints (30 and 90 days) showed progressive loss of the biolumines-
ence signal, indicating lossof viability (Fig. 3aandb). Therefore, the
se of integrase-defective LVs still conferred high viability of iDCs
n vivo, albeit at a considerably lower risk of potential genotoxicity.
.5. Allogeneic CD3+ T cell stimulation with iDCs: MLR and
ytokine proﬁle
As a ﬁrst method used to evaluate the antigen-presentation
apability of the iDCs, we performed mixed lymphocyte reactions
MLR, Fig. 4). PBMCs (freshly thawed) or iDCs (differentiated in cul-
ure for 7 days) were used as antigen presenting cells (APCs) to
timulate allogeneic CD3+ T cells. APCs were co-cultured with T
ells at various ratios for 6 days. Both types of iDCs stimulated
cell expansion. SmartDCs produced signiﬁcantly higher levels
nd dose-dependent T cell stimulation than SmyleDCs (Figs. 4ach surface marker (CD14, HLA-DR, CD86, CD80, CD209 and CD123) expressed on
ely. Averages and SD were calculated from independent experiments with samples
and S8a and b). The levels of cytokines accumulated in the MLR
culture supernatants (APC to T cell ratio 1:5) were measured by
bead array. High levels of IFN- and TNF- (>400pg/ml) were
detectable in supernatants of T cells stimulated with both iDCs.
In addition, several other cytokines were detectable at moderate
levels (20–100pg/ml), such as IL-2, IL-4, IL-5 and IL-6, indicating
a mixed pattern of cytokines that could be produced by Th1, Th2,
Th17 and Th22 cells. IL-8 was produced at high levels for all three
MLR cultures (Fig. 4b).
3.6. Stimulation of NK cells with autologous iDCs
Previous studies have indicated that DCs generatedwith recom-
binant GM-CSF and IFN-might have cytolytic activity against cells
lacking class I MHC, suggesting similar function as Natural Killer
(NK) cells [28]. iDCs showed no evidence of direct cytolytic activity
toward K562 cells labeled with chromium after 4h of co-culture
(Fig. S5a). Since the cytolytic activity could be indirectly provided
by NK cells, we evaluated on another set of experiments if iDCs
could in turn stimulate NK cells. NK cells co-cultured with autol-
ogous SmartDCs were not activated, whereas NK cells co-cultured
with SmyleDCs were activated, as modest increased frequencies of
IFN- (p=0.161) and TNF- (p=0.045) positive NKs were observed
(Fig. S5b and c).
3.7. In vitro stimulation of CD8+ T cells with autologous
conventional or iDCs loaded with pp65 peptides
We evaluated whether CD8+ T cells obtained from a CMV-
seropositive donor could be stimulated in vitro with Conventional
DCs or iDCs pulsed with pp65 peptides and result in the expan-
sion of pp65-speciﬁc T cells. iDCs produced with donor monocytes
and maintained in culture for 7 days were loaded with a pp65
overlapping peptide pool and used to stimulate autologous CD8+
T cells. After 7 days of stimulation, the CD8+ T cell cultures were
analyzed for production of several cytokines (Figs. 5a and 6a).
pp65-antigenic stimulation by the iDCs was required for high pro-
duction of IFN- (produced by activated CTLs) and, surprisingly,
also for high production of IL-13 (a cytokine typically produced
by activated Th2 cells). IL-5, a cytokine typically secreted by T
effector memory cells, was higher for iDC than for conventional
DCs with pp65 antigenic stimulation. Production of TNF- and IL-8
were also stimulated with antigen, albeit their production by con-
ventional DCs or by iDCs was less dependent on pp65 peptides.
Stimulation with conventional DCs or with iDCs loaded with pp65
peptides resulted in a substantial (2- to 3-fold) increase in T cell
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Fig. 3. Viability of SmyleDCs and SmartDCs in vivo in NRG mice. (a) In vivo optical imaging analyses of ﬂanks of NRG mice where iDC/fLUC were subcutaneously injected.
After intraperitoneal administration of Luciferin, bioluminescent signals were detectable on 7, 14, 30 and 90 days corresponding to the iDC/fLUC injection sites. The reference
color bar indicates minimum of bioluminescent signal in blue and maximum signal in red. (c) Averages of bioluminescent signals emitted from injection sites were quantiﬁed
and represented as radiance mean (p/s/cm2/sr), n=3 mice/group.


































Fig. 4. Mixed lymphocyte reactions performed with SmyleDCs and SmartDCs. (a) T cells stimulated with allogeneic APCs (PBMC, SmyleDC or SmartDC) in mixed lymphocyte
reactions were analyzed for T cell proliferation. APCs were co-cultured with various numbers of allogeneic CD3+ T cells at ratios of 1–2, 5 and 20 for 6 days. Incorporated
thymidine was measured as counts per minute (cpm) and the stimulation index was calculated using T cells maintained without APCs as reference. (c) Cytokines secreted
by T cells in MLR. IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-, GM-CSF and TNF- were detected by multiplex luminex bead array analyses of supernatants collected from
MLR cultures (1 APC to 5T cell ratio). Averages and SD were calculated from independent experiments with samples from three different APC donors, n=3, *p<0.05.
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Fig. 5. Conventional IFN--DCs versus SmyleDCs loaded with pp65 peptide pool for T cell stimulation: (a) Detection of IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12,
IL-13, IFN-, GM-CSF, MCP-1 and TNF- by luminex bead array analyses (pg/ml; supernatants collected on day 7). (b) Number of viable T cells (×106 cells) after 7 days of















etimulation with different APCs. An irrelevant tetramer (white), or pp65-restricte
aseline of pre-existing pp65 reactivity of this donor was shown as PBMC group. (d a
r T effector memory (TEM, CD45RA−CD62L−) cells within pp65-reactive CD8+ T ce
umbers in comparison with the unloaded DCs (Figs. 5b and 6b).
he detection of pp65-reactive CD8+ T cells in the cultures was
erformed with tetramers speciﬁc to two pp65 epitopes (NLVP-
VATV: restricted to HLA-A*0201 and TPRVTGGGAM: restricted
o HLA-B*0702) and ﬂow cytometry analyses (Figs. 5c and 6c).
he baseline frequency of CD8+ T cells reactive against these epi-
opes prior to stimulation was approximately 3%. After stimulation
ith conventional DCs or iDCs pulsed with the peptides, the fre-
uencies increased to 33% (11-fold) for SmyleDC+pp65 and to
0% (6-fold) with SmartDC+pp65. Conventional DCs or iDCs that
ere not loaded with pp65 antigen did not lead to a noticeable
xpansion of pp65-reactive T cells. The pp65-reactive T cells thatamers (A*0201-NLVPMVATV: grey/B*0702-TPRVTGGGAM: black) were used. The
Bar charts representing the frequency of T central memory (TCM, CD45RA−CD62L+)
ulation detectable by tetramer analyses.
were expanded after the 7 days of stimulation with iDCs pulsed
with pp65 antigens were further analyzed for the distribution of
T central memory (TCM: CD45RA−/CD62L+) and T effector mem-
ory (TEM: CD45RA−/CD62L−) (Figs. 5d, e and 6d, e). Altogether, the
data indicated comparable effects of conventional DCs versus iDCs
in the stimulation of CTL responses when the antigenic epitopes
were provided exogenously as peptides. One particular aspect that
seems to favor the stimulation of CTLs by SmyleDCs pulsed with
peptides is that these cells did not require maturation with exoge-
nous cytokines to reach the plateau of stimulation and, therefore,
seem to be intrinsically more activated than conventional DCs or
SmartDCs (Fig. S6c and d).
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Fig. 6. Conventional IL-4-DCs versus SmartDCs loaded with pp65 peptide pool for T cell stimulation: (a) Detection of IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13,
IFN-, GM-CSF, MCP-1 and TNF- by luminex bead array analyses (pg/ml; supernatants collected on day 7). (b) Number of viable T cells (×106 cells) after 7 days of culture.
(c) Analyses of pp65-speciﬁc T cells by tetramer analyses. Bar chart represents percentage of pp65 reactive CD8+ T cells after 7 days of culture (no APC) or after stimulation









dxisting pp65 reactivity of this donor was shown as PBMC group. (d and e) Bar char
emory (TEM, CD45RA−CD62L−) cells within pp65-reactive CD8+ T cell population
.8. In vitro stimulation of autologous CD8+ T cell responses with
DCs co-expressing pp65
T cell stimulation with DCs loaded exogenously with peptides
ould not elucidate the actual processing of the pp65 antigen
nside the cells. In addition, a long-lived DC vaccine capable of
table presentation of endogenously processed epitopes could gen-
rate multiantigenic and multifunctional responses. An integrase
efective lentiviral vector expressing pp65 used to co-transduceresenting the frequency of T central memory (TCM, CD45RA−CD62L+) or T effector
ctable by tetramer analyses.
SmyleDCs andSmartDCsproduced stable expressionof the antigen,
without affecting their viability or DC phenotypes (Fig. 7a). Quan-
titative detection of pp65 in SmyleDCs/pp65 or SmartDCs/pp65
by intracellular staining and ﬂow cytometry analyses, showed
pp65 expression in approximately 80% of the cells (Fig. 7a).
Day 7 Conv-IFN--DCs, SmyleDCs generated with ID-LVs and
SmyleDCs generated with IC-LVs resulted in similar stimulation
of allogeneic or autologous T cells in MLR (Fig. S7a and b). For
SmartDCs, DCs programmed with IC-LVs were more stimulatory
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Fig. 7. SmyleDCs versus SmartDCs co-expressing full-length pp65 for stimulation of T cells. (a) Co-expression of pp65 in SmyleDCs and SmartDCs after co-transduction with
ID-LV-pp65. Representative histogram analyses showing the frequency of iDCs with detectable intracellular pp65 expression, which was correlated with the frequency of
cells positive for HLA-DR and CD86markers. Analyseswere preformed for culturesmaintained for 7, 14 or 21 days in vitro. (b) Frequency of pp65-speciﬁc CD8+ T cells detected












tlack). (c) Frequency of TCM and TEM cells within the pp65-reactive CD8 T cell po
ith CD45RA and CD62Lmarkers. (d) IFN- producing T cells were detected by ELISP
black bar). Un-pulsed stimulated T cells were represented as white bars. Average n
n MLR (Fig. S8a and b). For pp65-speciﬁc T cell stimulation,
DCs generated with IC-LVs were superior, but conventional DCs
nd iDCs generated with ID-LV were equally stimulatory as well
Figs. S7c, d and S8c, d). Therefore, the co-transduction with two
D-LVs (one expressing the antigen and the other expressing the
ytokines) was shown as a feasible approach for generating func-
ional antigen-loaded iDCs and was further explored due to its
mproved safety advantages.
We performed additional assays in order to better characterize
he phenotypes of T cells generated upon stimulation with iDCsons. T cell phenotypes naïve (N, white), TCM (grey), TEM (black) were determined
say. 20,000 stimulated CD8+ T cells seeded perwell were pulsedwith pp65 peptides
r of spots from duplicate wells was quantiﬁed.
generated upon co-transduction of two ID-LVs. We used a simi-
lar experimental scheme used for stimulations with iDCs pulsed
with peptides, except that T cells had to be stimulated twice
in vitro in order to generate higher frequencies of T cells that
could be analyzed by tetramers speciﬁc against two pp65 epi-
topes. Non-stimulated and iDC-stimulated T cells were harvested
for tetramer analyses and IFN- ELISPOT. The results for both
assays showed higher stimulation of CD8+ responses when using
SmartDCs/pp65 than SmyleDCs/pp65 (Fig. 7b and d). Notwith-
standing, the frequency T central memory cells were higher
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Fig. 8. SmyleDCs versus SmartDCs co-expressing full-length pp65 for stimulation of CD8+ T cell response in vivo. (a) Control NRG mice (injected with PBS) or mice immunized
with SmyleDCs/pp65 or with SmartDCs/pp65 were injected intravenously with autologous CD8+ T cells 7 days later. Frequency of human CD3+/CD8+ T cells detected in PBL
of NRG mice 14 days after CD8+ T cell infusion is shown as percentage of the total PBMCs in the blood. (b) CD3+/CD8+ T cells recovered from the blood of NRG mice were
analyzed for pp65 reactivity. Frequency of T cells detected by tetramers reactive against two pp65 epitopes (A*0201 and B*0702) are represented as averages. Averages and
S + from m +
f /pp65
















tD were calculated from 3 mice per group, *p<0.05. (c) Human CD8 T cells isolated
rom splenocytes of mice (PBS or immunized with, SmyleDC/pp65 or with SmartDC
grey bar) or with a CEF peptide mix used as recall antigen control (black bar). Contr
howed baseline or no reactivity. n.d. = not detectable. Each bar represents the aver
fter stimulation with SmyleDC/pp65 than with SmartDC/pp65
Fig. 7c). The stimulation with SmartDCs/pp65 seemed to favor the
xpansion of T effector memory cells, producing higher levels of
FN-.
.9. In vivo pp65-speciﬁc immune responses after immunization
ith iDCs co-expressing pp65
We have previously demonstrated that SmartDCs engineered
ith IC-LVs and co-expressing pp65 substantially accelerated CD8+
unctional anti-pp65 responses in NRG mice [10]. In a similar
xperimental setting as we had described before, SmyleDCs/pp65
r SmartDCs/pp65 programmed with ID-LVs were used as s.c.
accines to precondition mice prior to infusion with autologous,
nstimulated CD8+ T cells. 14 days after T cell infusion, PBL and
pleen were analyzed. As previously observed, the frequency of
uman CD3+CD8+ T cells detectable in PBL of mice precondi-
ioned with SmartDC/pp65 was signiﬁcantly higher than in PBLice spleen were assayed for functionality by IFN- ELISPOT. CD8 T cells recovered
) were seeded at 10,000 cells per well and primed in vitro with a pp65 peptide pool
lls that were not re-primed in vitro with the pp65 peptides and assayed for ELISPOT
2 mice/group.
of control mice injected with PBS (Fig. 8a). A higher experimen-
tal variation was obtained for the frequencies of human CD3+CD8+
T cells detectable in PBL of mice injected with SmyleDC/pp65,
but the mean was slightly superior to the results obtained with
the SmartDC/pp65 vaccination. In order to assess pp65-reactivity,
human CD3+CD8+ T cells detectable in the PBL were analyzed
by tetramer staining. The frequencies of pp65-speciﬁc circulat-
ing CD3+CD8+ T cells were approximately eight-fold higher in
mice preconditioned with SmyleDC/pp65 or SmartDC/pp65 as
compared to control mice (Fig. 8b). Human CD3+CD8+ T cells
were isolated from the spleen by FACS sorting and used in IFN-
ELISPOT assay. The human T cells were pulsed with pp65 pep-
tide pool or with a mixture of recall antigenic peptides. Using this
approach, we were able to conﬁrm the engraftment and expan-
sion of functional human CD3+CD8+ T cells in the spleen (Fig. 8c).
Mice injected with SmyleDC/pp65 showed higher frequencies of
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. Discussion
Cytomegalovirus is a relevant issue in stem cell transplantation,
articularly because immune suppressed transplanted patients do
ot respond well to vaccinations, underscoring the need for novel
ell-based therapies. With respect to existing DC vaccination ther-
pies, they are very cost intensive, poorly viable in vivo, scarcely
io-distribute to lymphatic tissues and are far away from a stan-
ardized cellular product for larger clinical trials [29]. We have
reviously demonstrated in homologous and humanized mouse
odels that SmartDCs generated with IC-LV are signiﬁcantly more
iable in vivo (several weeks) than conventional DCs (1–2 days)
nd immunization with SmartDCs result into massive recruitment
nd expansion of antigen-reactive T cells in lymph nodes or in
he vaccination site [5,6,10]. Spilucel-T, the only FDA approved
nd marketed cell therapy product, is not a highly stable product
nd therefore has to be prepared fresh for three rounds of infu-
ion. We have recently demonstrated the feasibility of up-scaling
martDC production using GMP-compatible methods, which was
chieved in 28h of ex vivo cell manipulation and the cell prod-
ct could be conveniently cryopreserved without precluding its
otency [7]. Although novel in the ﬁeld of immunotherapy, lentivi-
al vectors have now lined up for several clinical trials of human
ene therapy (for hematopoieitic, metabolic and neurologic disor-
ers), and large scale GMP production is developing in Europe and
n the United States [30,31]. Thus, innovative genetically modiﬁed
DCs may become a practical and valuable option for immunother-
py of immune-compromised transplanted patients at risk of CMV
nfection, since besides its reduced time of ex vivo manipulation,
igh viability in vivo and antigenic properties, its 2–3 weeks pro-
uction of cytokine stimuli may improve the immunization milieu
nd accelerate the homeostatic immune reconstitution of human T
ells.
Our ﬁrst goal in this current work was to explore ID-LVs in the
ransduction of monocytes with the potential purpose of reducing
he risk of insertionalmutagenesis in iDCs. Thus,we testedwhether
e could produce LVs containing a mutation in one of the pack-
ging vectors that disabled the integrase protein in the lentivirus
article (and thus prevented integration of the provirus reverse-
ranscribed DNA) [14,15]. We demonstrated that ID-LVs could be
roduced at high titers and were effective at transducing human
onocytes. Upon terminal differentiation of the iDCs, expression
f the transgenes (cytokines and antigen) persisted for 3 weeks.
he constitutive and robust expression of cytokines (GM-CSF/IFN-
for SmyleDC and GM-CSF/IL-4 for SmartDC) enabled generation
f stable and functional iDCs that could self-differentiate in vitro
r in vivo. Since we noticed a modest (10–15%) gene marking
f monocytes transduced with ID-LV-GFP, it is possible that ID-
Vs expressing the cytokines needed for iDC differentiation and
aintenance provide a selective advantage for the transduced
onocytes for about 3 weeks. A previous report demonstrated that
ifferentiated human APCs (DCs and macrophages maintained in
ulture for 4 and 8 days, respectively) could be transduced with
D-LVs [20], but the current work is the ﬁrst demonstration that
onocytes can also be effectively transduced with ID-LVs prior to
heir differentiation, which then maintain the DCs functional and
live.
The capability of ID-LVs to infect monocytes seems to reﬂect
hat occurs during natural HIV-1 infection, as monocytes are one
f the relevant HIV-1 reservoirs [32]. During initial infection (i.e.,
n non-activated monocytes and CD4+ T cells), most of the viral
DNA exists as unintegrated linear DNA form (for which fewer
opies eventually integrate), or nuclear circular forms, which can
ead to “abortive” defective integrations or are ultimately degraded
for a review, see [33]). Nevertheless, prior to HIV-1 integra-
ion, transcription and translation of viral genes present in theine 30 (2012) 5118–5131 5129
unintegrated DNA forms is observed which initiate a rapid
sequenceof events to shut-downtheantigen-presentationmachin-
ery (such as down-regulation of MHC class I expression via Nef
[34]).
Ironically to the natural biology of HIV-1 hindering DC dif-
ferentiation, HIV-1-derived ID-LVs co-expressing combinations of
cytokines were actually able to potently induce DC differentia-
tion. Other groups had previously reported the transduction of
monocytes by LVs, but since these studies lacked of the 8h GM-
CSF/IL-4 pre-conditioning step to activate the monocytes prior to
LV transduction [35,36], the gene transfer efﬁciency was usually
low. Co-expression of GM-CSF/IFN- or GM-CSF/IL-4 was readily
observed in the monocytes preconditioned with cytokines and
transducedwith ID-LVswhich induced their promptdifferentiation
into highly stable and immunologically competent APCs. During
the in vitro culture period, we did not observe cytopathic effects
of the integrase-defective lentivirus as the cells were remarkably
viable and cell death and senescence was mostly noticeable only
at about 3 weeks after ID-LV gene transfer (which parallels the
expected life-span of “natural” DCs). NRG mice injected into the
skin with SmyleDCs and SmartDCs and analyzed by non-invasive
optical imaging analyses showedgradual disappearance of the iDCs
within 1 month after administration. Mice maintained in observa-
tion for up to 100 days post-injection showed no signs of disease.
In summary, the results obtained with ID-LVs, were remarkably
similar to previous observations using IC-LVs for genetically pro-
gramming iDCs [10].
Thus, as a logical progression, the two types of safety-enhanced
ID-LVs were further compared regarding their capabilities to
induce DCs with different immunologic properties (Table 1). The
combination of recombinant GM-CSF/IFN- has been extensively
compared with GM-CSF/IL-4 for generation of DCs [37–40]. In
their work for the development of therapeutic DC vaccines against
hepatitis C virus (HCV), Santini and collaborators proposed that
IFN--DCs were “directly licensed” or more readily matured for
cross-presenting low amounts of viral antigens by mechanisms
likely involving the expression of IL-12 [39]. Our results com-
paring the autonomous ID-LV expression of GM-CSF/IFN- with
GM-CSF/IL-4 conﬁrms some of the previous ﬁndings obtained
with the recombinant cytokines, although in terms of expres-
sion of relevant immunologic markers and inﬂammatory cytokines
the two types of iDCs were remarkably similar (Table 1). Recent
work in our laboratory analyzing the RNA expression pattern of
conventional IL-4-DCs versus SmartDCs showed for the later up-
regulation of several downstream genes involved with interferon
regulatory circuits (Sundarasetty et al., in preparation), explain-
ing the convergence of SmartDCs with SmyleDCs. The SmyleDC
immunophenotypic characterization corroborated with previous
ﬁndings that DCs grown in the presence of IFN- (instead of
IL-4) lacked expression of CD209 (DC-SIGN). These results was
expected, as DC-SIGN expression is dependent on the IL-4 cytokine
but negatively regulated by IFN- [41]. DC-SIGN is known to
bind to several types of viruses and although its function might
be related to T cell activation, pathogens seem to use this route
to “hijack” DCs and modulate them [42]. Thus, since DC-SIGN
is a potential target for the capture of DCs by pathogens, its
down-regulation in a cell vaccine might be a positive hallmark
enabling them to escape pathogen infection. It was previously
reported that DCs generated in the presence of IFN- dis-
played NK-like cytotoxicity and a mature immunephenotype [43].
SmyleDCs were not able to lyse K562 cells directly, but modestly
stimulated NK cells in vitro (Fig. S4a).Overall, in terms of expression of relevant immunopheno-
typic markers and endogenous cytokines, iDCs maintained in vitro
seemed to be equivalent to tissue-resident DCs, which can uptake
andpresent antigen effectively. Usingpp65 soluble peptides loaded
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Table 1
Characteristics of SmyleDCs and SmartDCs.
Property SmyleDC SmartDC
DC viability in vitro (14 days) Comparable Comparable
DC viability in vivo (30 days) Comparable Comparable
DC immuno-phenotype Stably high: HLA-DR, CD86, CD80; low: CD209
(DC-SIGN), CD14, CD123
Stably high: HLA-DR, CD86, CD80, CD209; low:
CD14, CD123
Transgenic cytokine expression GM-CSF stable (>1ng); IFN- stable (>5ng day
14)
GM-CSF stable (>1ng); IL-4 decreasing (<1ng,
day 14)
Up-regulated endogenous cytokines IFN-, IL-2, IL-5, IL-6; higher IL-8 IFN-, IL-2, IL-5, IL-6, IL-8
CD3+ T cell stimulation in MLR (Thymidine incorporation) Lower Higher
NK activation in vitro Modest None
pp65 peptide loading and/CD8+ T cell stimulation in vitro Does not require exogenous maturation with
cytokines
Augments upon exogenous maturation with
cytokines
Co-expressed pp65/CD8+ T cell stimulation in vitro Epitope-speciﬁc higher TCM frequencies TEM remains as preponderant population;
higher IFN- production













































vpp65/CD8 T cell stimulation in vivo Higher reactivit
from spleen
xternally on iDCs, both SmyleDCs and SmartDCs potently stim-
lated T cells to proliferate and upregulated the production of
everal inﬂammatory cytokines (IFN-, IL-3, GM-CSF, TNF-, IL-
, IL-5), resulting into “licensed antigen presentation” of different
p65 antigenic determinants in vitro (20–30% of the cells stim-
lated in vitro for 7 days were reactive against pp65 epitopes).
he pp65-reactive T cells stimulated in vitro with peptides were
n the majority characterized as T central memory (TCM, 43–58%)
nd T effector memory (TEM, 40–47%) phenotype. Interestingly,
myleDCs bypassed the requirement of additional in vitro matura-
ion with recombinant cytokines for optimal antigen-speciﬁc T cell
timulation (Fig. S7), indicating that SmyleDCs are more endoge-
ously activated than SmartDCs.
When the pp65 antigen was provided internally, in the form
f a full-length pp65 antigen expressed stably for 3 weeks by a co-
ransduced ID-LV,weobservedpotent stimulationof pp65-reactive
ultivalent T cells in vitro (Figs. 5 and 6). Notably, in this setting the
ajorityof theTcellsdisplayedaTEMphenotype (although10–40%
f TCM were also observed); possibly indicating that pp65 internal
rocessing by the iDCs per se provided higher immune stimulation.
oreover, these iDCs were endowed with potent functional activ-
ties in vivo, as they were able to directly stimulate the generation
f effector CD8+ T cell responses in NRG mice reconstituted with
uman lymphocytes. Since NRG mice lack a functional lymphatic
ystemand lymphnodes towhere iDCs couldmigrate to, it is there-
ore likely that iDCs stimulated T cells directly on the immunization
ites.
Based on these results, the use of SmyleDCs or SmartDCs co-
xpressing pp65 for the development of prophylactic vaccines to
oost the immune response in lymphopenic hosts at high risk
f HCMV infection should be considered. It has been demon-
trated that the transfer of adoptive immunity against HCMV after
SCT depends on the speciﬁcity and memory phenotype of spe-
iﬁc T cells in the donor [44]. Thus, a potential population target
or vaccination in order to avoid HCMV recurrent reactivations
ould be immunosuppressed HCMV seropositive recipients of
rafts from seropositive or seronegative donors. After transplan-
ation, recipients would be vaccinated with iDCs produced from
onor’s monocytes in order to minimize graft-versus-host disease.
Regarding the choice between the two types of iDCs for
n antiviral vaccine, it is tempting to speculate that SmyleDCs
ould be the ﬁrst choice, based on several proposed superior
ttributes conferred to DCs produced in the presence of IFN-
instead of IL-4 which led to a recent clinical trials using
x vivo generated DCs as vaccines for chronically infected HIV-
patients (http://clinicaltrials.gov/ct2/show/NCT00796770) [21].
verall, based on the data presented, SmyleDCs showed two
ery interesting novel properties: NK stimulation and higherD8 T cells recovered Comparable reactivity in CD8 T cells
recovered from peripheral blood
stimulation of TCM CD8+ T cell responses. Combined, these proper-
ties could ideally result in prompt NK innate immune responses,
allied with high adaptive T cell long-term memory responses
against HCMV.
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